Press releases

STORM Therapeutics Virtual Conference Calendar

26 November 2020, Cambridge, UK: STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, today announces that the STORM Therapeutics’ will be attending the following virtual conferences.

26th November 2020: 31st Symposium on Medicinal Chemistr

Wesley Blackaby, Vice President Chemistry, will be presenting “The challenges of targeting RNA modifying enzymes as drug targets” at 1.45pm GMT.

The Symposium on Medicinal Chemistry in Eastern England, known as the "Hatfield MedChem" meeting, is a highly successful, long-standing, one-day annual meeting. The scientific programme will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemists. Wesley’s presentation will include an introduction to RNA modifications and go on to describe some of the strategies and technologies STORM has developed to tackle this target class using the METTL3 program as a case study.

10th December 2020: 3rd Annual RNA-Target Drug Discovery

Wesley Blackaby, Vice President Chemistry, will be presenting “Targeting Cancer with First-in-Class Inhibitors of the RNA m6A Methyltransferase METTL3” at 11:30am EST (4:30 pm GMT).

The 3rd RNA- Targeted Drug Discovery Summit is the most comprehensive and definitive event for the RNA targeting small molecule community. Wesley’s presentation will include an introduction to RNA modifications, the role of METTL3 and the m6A modification in disease and describe the discovery of potent and selective inhibitors of METTL3 including their utility in haematological and solid tumours.


STORM Therapeutics Ltd
Keith Blundy
T: +44 (0)1223 804174

Optimum Strategic Communications
Mary Clark, Eva Haas, Shabnam Bashir
Tel: +44 (0)203 950 9144



STORM Therapeutics, founded in 2015, is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. Storm is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.

STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences and IP Group, who share the team’s ambitions to build a world-leading company in the field.